NCT00377520View on ClinicalTrials.gov

A Trial for Patients With Advanced/Recurrent Endometrial Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

October 31, 2007

Study Completion Date

September 30, 2008

Conditions
NeoplasmsNeoplasms by SiteUrogenital NeoplasmsGenital Neoplasms, FemaleUterine NeoplasmsEndometrial NeoplasmsCancer of EndometriumEndometrial CancerCancer of the EndometriumEndometrium CancerNeoplasms, Endometrial
Interventions
DRUG

pemetrexed

900 mg/m2, intravenous (IV), every 21 days, until disease progression

Trial Locations (1)

19103

Gynecologic Oncology Group 215-854-0770, Philadelphia

All Listed Sponsors
collaborator

Gynecologic Oncology Group

NETWORK

lead

Eli Lilly and Company

INDUSTRY

NCT00377520 - A Trial for Patients With Advanced/Recurrent Endometrial Cancer | Biotech Hunter | Biotech Hunter